Origami 2(DE3) Competent Cells - Novagen

Genotype: Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139ahpC galE galK rpsL F′[lac⁺ lacI^q pro] (DE3) gor522::Tn10trxB (Str^R, Tet^R)





This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.

Origami 2 strains have mutations in glutathione reducatase (gor) and thioredoxin reductase (trxB), facilitating proper disulfide bond formation.

Origami 2 host strains are K-12derivatives that have mutations in both thethioredoxin reductase (trxB) and glutathionereductase (gor) genes, which greatly enhancedisulfide bond formation in the E. colicytoplasm. The Origami2 strains are kanamycin sensitive; like theoriginal Origami strains, the gor mutation is still selectedfor by tetracycline. To reduce the possibility ofdisulfide bond formation between molecules,strains containing mutations in trxB and gor arerecommended only for the expression of proteinsthat require disulfide bond formation for properfolding.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlOrigami 2(DE3) Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

Toxicity: Multiple Toxicity Values, refer to MSDS (O)

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany